Apicoplast metabolism: Parasite’s achilles’ heel

Kavita Kadian, Yash Gupta, Harsh Vardhan Singh, Prakasha Kempaiah, Manmeet Rawat

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Malaria continues to impinge heavily on mankind, with five continents still under its clasp. Widespread and rapid emergence of drug resistance in the Plasmodium parasite to current therapies accentuate the quest for novel drug targets and antimalarial compounds. Plasmodium parasites, maintain a non-photosynthetic relict organelle known as Apicoplast. Among the four major pathways of Apicoplast, biosynthesis of isoprenoids via Methylerythritol phosphate (MEP) pathway is the only indispensable function of Apicoplast that occurs during different stages of the malaria parasite. Moreover, the human host lacks MEP pathway. MEP pathway is a validated repertoire of novel antimalarial and antibacterial drug targets. Fosmidomycin, an efficacious antimalarial compound against IspC enzyme of MEP pathway is already in clinical trials as a combination drugs. Exploitation of other enzymes of MEP pathway would provide a much-needed impetus to the antimalarial drug discovery programs for the elimination of malaria. We outline the cardinal features of the MEP pathway enzymes and progress made towards the characterization of new inhibitors.

Original languageEnglish (US)
Pages (from-to)1987-1997
Number of pages11
JournalCurrent Topics in Medicinal Chemistry
Volume18
Issue number22
DOIs
StatePublished - 2018

All Science Journal Classification (ASJC) codes

  • Drug Discovery

Fingerprint

Dive into the research topics of 'Apicoplast metabolism: Parasite’s achilles’ heel'. Together they form a unique fingerprint.

Cite this